Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera

• Autors principals: Aaron T Gerds (Autor), Claudia Castro (Autor), Frank Snopek (Autor), Megan M Flynn (Autor), Alexandra G Ellis (Autor), Meredith Mannin (Autor), Ray Urbanski (Autor)
• Format: Llibre
• Publicat: Becaris Publishing Limited, 2023-08-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi R ) was approved in the US to treat adults with PV. The purpose of thi...